Prestarium A, 5 mg 30 pcs

Perindopril is an inhibitor of the enzyme that converts angiotensin I to angiotensin II (ACE inhibitor). ACE both converts angiotensin I into the vasoconstrictor angiotensin II and degrades bradykinin, which has a vasodilator effect, into an inactive heptapeptide. Perindopril reduces total peripheral vascular resistance, which leads to a decrease in blood pressure, normalizes heart function by reducing preload and postload.

Indications

Active ingredient

Composition

Prestarium® A 5 mg, 10 mg: dispersible oral tablets containing 5 mg, 10 mg of perindopril arginine. Prestarium® A 5 mg, 10 mg: coated film-coated tablets containing 5 mg, 10 mg of perindopril arginine. As excipients contain aspartame (dispersible tablets) and lactose.

How to take, the dosage

Interaction

Contraindicated with:aliskiren (in patients with diabetes and/or impaired renal function); APA II in patients with diabetic nephropathy; extracorporeal therapy; combination of valsartan + sacubitril.

Do not recommend with:aliskiren (in patients without diabetes or renal dysfunction), APA II, estramustine, potassium-saving diuretics (triamterene, amiloride) or potassium salts, potassium-containing products and supplements, lithium drugs.

With special caution:. hypoglycemic agents (insulin, oral hypoglycemic agents except glyptins), baclofen, potassium-saving diuretics, potassium-saving diuretics (eplerenone, spironolactone), nonsteroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid ≥3 g/day, racecadotril, mTOR inhibitors (e.g., sirolimus, everolimus temsirolimus), alteplase.

With definite caution: hypotensive drugs, vasodilators, glyptins (linagliptin, saxagliptin, sitagliptin, wildagliptin), tricyclic antidepressants, antipsychotics (neuroleptics) and general anesthesia agents, sympathomimetics, gold drugs.

Drugs that cause hyperkalemia: Aliskiren, potassium salts, potassium-saving diuretics, IAPPs, ARA II, NSAIDs, heparins, immunosuppressants such as cyclosporine or tacrolimus, trimethoprim, sulfamethoxazole/trimethoprim (Co-trimoxazole).

Special Instructions

Ensensitivity/angioneurotic edema:The drug should be stopped and the patient should be observed until the signs of edema disappear completely. Angioneurotic edema accompanied by laryngeal edema may be fatal. Co-administration with the combination valsartan + sacubitril (contraindicated; use of one drug at least 36 hours after discontinuation of the other), or with other neprilysine inhibitors (e.g., ratsecadotril), or with mTOR inhibitors (e.g., sirolimus, everolimus, temsirolimus) or with glyptins (linagliptin, saxagliptin, sitagliptin, vildagliptin) – increases the risk of angioedema (e.g., swelling of the tongue, vocal folds, or larynx with or without airway obstruction).

Anaphylactoid reactions in hemodialysis using high-flow membranes:Prescribing a different class of hypotensive drug or using a different type of dialysis membrane.

Anaphylactoid reactions during low-density lipoprotein apheresis:In rare cases, life-threatening anaphylactoid reactions may develop. Temporarily discontinue iAPP therapy before each procedure.

Anaphylactoid reactions during desensitization: Stop iAPP therapy temporarily before each procedure. Such reactions may have developed again if treatment was accidentally or carelessly resumed.

Neutropenia/agranulocytosis/thrombocytopenia/anemia:With particular caution use in patients with systemic connective tissue disease, against the background of taking immunosuppressants, allopurinol or procainamide. Periodically monitor the leukocyte count in blood.

Contraindications

Side effects

Frequently:dizziness, headache, paresthesia, vertigo, visual disturbance, tinnitus, hypotension, cough, shortness of breath, abdominal pain, constipation, diarrhea, taste disorder (dysgeusia), dyspepsia, nausea, vomiting, skin itching, skin rash, muscle spasms, asthenia.

Infrequent:. eosinophilia, hypoglycemia, hyperkalemia, hyponatremia, mood lability, sleep disturbance, drowsiness, fainting, palpitations, tachycardia, vasculitis, bronchospasm, dry mouth, urticaria, angioedema of face, lips, extremities, mucous membranes, tongue, of the vocal folds and/or larynx, photosensitivity reactions, pemphigoid, increased sweating, arthralgia, myalgia, renal failure, erectile dysfunction, chest pain, malaise, peripheral edema, fever, increased blood urea and creatinine concentrations, fall.

Pseldom: aggravation of psoriasis, increased liver enzyme activity and blood bilirubin concentration.

Very rare: .agranulocytosis or pancytopenia, decreased hemoglobin and hematocrit, leukopenia/neutropenia, hemolytic anemia in patients with congenital deficiency of glucose-6-phosphate dehydrogenase, thrombocytopenia, confusion, angina pectoris, arrhythmia, myocardial infarction and stroke, eosinophilic pneumonia, rhinitis, pancreatitis, hepatitis (cholestatic or cytolytic), erythema multiforme, acute renal failure.

Frequency unknown: Rainault syndrome. Inadequate antidiuretic hormone secretion syndrome (SNSADH) has been reported when coadministered with other ACE inhibitors. SNSADH can be considered a very rare possible complication associated with treatment with ACE inhibitors, including perindopril.

Pregnancy use

Similarities